Top Stories
Credence's drug delivery devices address industry challenges in injectable drug delivery, while maintaining use of off-the-shelf syringe barrels and other primary package components in order to facilitate implementation for its pharma customers.
The investment will be directed towards scaling of production capacity for the Credence Companion® and Dual Chamber Reconstitution Systems as well as development of other members of the Company’s platform of innovative drug delivery systems, including its connected health portfolio.
Senior Executives Greg Knight and Chester Aldridge have begun a long term executive level advisory engagement to actively guide leadership of Brillouin Energy Corp.’s next stage of development.
Aldridge Tapped to Promote DataShapes' Patented Technology That Transforms Data at the Edge and Brings Insight to the Enterprise.
Aelan's novel technology is a combination device for the controlled, versatile and measured production of biologics which has been positioned as a new generation of regenerative therapy products for multiple indications.
The agreement gives Aelan world-wide rights to intellectual property. Aelan Cell Technologies today announced a licensing agreement with the Buck Institute for Research on Aging (Novato). The agreement gives Aelan world-wide rights to intellectual property describing a novel epigenetic biomarker with a granted United States patent.
News
An early human clinical feasibility study has indicated that serological tests using the biomarker alongside other proprietary components developed by Aelan's researchers could potentially help physicians diagnose Alzheimer's disease (AD).
A recent study published in Proceedings of the National Academy of Sciences and conducted by a team of researchers at the Georgia Institute of Technology and Aelan Cell Technologies has identified regulatory elements that allow for the creation of a diverse range of different cell types from different genetic information.
Novartis has invested in Credence, confirming its interest in employing Credence technology for its injectable medicines.
The development project is meant to advance the safety of the Companion device for drug and vaccine products, which include storing drugs in dried form until time of use, Credence said in a news release.
Chester Aldridge, Chairman and CEO of US Equity Holdings, has joined Fraunhofer's Pompeii Sustainable Preservation Project (PSPP) as a Strategic Advisor.
Ventures
Aelan Cell Technologies is engaged in the research, discovery, development and commercialization of innovative biomedical technologies for the advancement of human health and longevity.
Mount Tam Biotechnologies is a specialty biopharmaceutical company focused on the discovery and development of novel mTOR modulators to address serious unmet need across a range of therapeutic areas.
PV Tech Group provides a comprehensive range of services to photovoltaic manufacturers, including full-scale integration of photovoltaic manufacturing facilities (wafers, cells, modules), strategic planning, technical evaluation, process optimization and project management.
Holdings
Credence MedSystems is a drug delivery and specialty pharmaceutical company focused on delivering medications safely for the benefit of our patients, caregivers and partners.
CURE is a preeminent developer and manufacturer of the most advanced oral thin film (CureFilm™) on the market today with an industry leading full service cGMP manufacturing facility.
Prosetta Biosciences, Inc. is biotechnology company focused on developing novel small-molecule antiviral therapeutics based on over 25 years of basic research on the Cell-Free Protein Synthesizing Systems (CFPSS).